MBX Biosciences (MBX) Competitors

$37.50 +0.52 (+1.41%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$37.66 +0.16 (+0.42%)

As of 04:43 AM Eastern

MBX vs. PCVX, KYMR, QGEN, TGTX, and MIRM

Should you buy MBX Biosciences stock or one of its competitors? MarketBeat compares MBX Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MBX Biosciences include Vaxcyte (PCVX), Kymera Therapeutics (KYMR), Qiagen (QGEN), TG Therapeutics (TGTX), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry.

How does MBX Biosciences compare to Vaxcyte?

MBX Biosciences (NASDAQ:MBX) and Vaxcyte (NASDAQ:PCVX) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

MBX Biosciences presently has a consensus target price of $60.22, suggesting a potential upside of 60.59%. Vaxcyte has a consensus target price of $86.00, suggesting a potential upside of 58.53%. Given MBX Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe MBX Biosciences is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

MBX Biosciences' return on equity of -24.52% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-24.52%	-23.59%
Vaxcyte	N/A	-32.51%	-29.51%

96.8% of Vaxcyte shares are held by institutional investors. 52.2% of MBX Biosciences shares are held by company insiders. Comparatively, 3.1% of Vaxcyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

MBX Biosciences has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market.

MBX Biosciences is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

In the previous week, MBX Biosciences had 27 more articles in the media than Vaxcyte. MarketBeat recorded 33 mentions for MBX Biosciences and 6 mentions for Vaxcyte. MBX Biosciences' average media sentiment score of 0.78 beat Vaxcyte's score of 0.48 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	6 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

MBX Biosciences beats Vaxcyte on 11 of the 14 factors compared between the two stocks.

How does MBX Biosciences compare to Kymera Therapeutics?

MBX Biosciences (NASDAQ:MBX) and Kymera Therapeutics (NASDAQ:KYMR) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

MBX Biosciences presently has a consensus target price of $60.22, suggesting a potential upside of 60.59%. Kymera Therapeutics has a consensus target price of $118.10, suggesting a potential upside of 37.98%. Given MBX Biosciences' higher probable upside, analysts clearly believe MBX Biosciences is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96

MBX Biosciences has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. MBX Biosciences' return on equity of -24.52% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-24.52%	-23.59%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

MBX Biosciences has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.06, indicating that its stock price is 106% more volatile than the broader market.

MBX Biosciences has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
Kymera Therapeutics	$39.21M	179.56	-$311.35M	-$3.57	N/A

In the previous week, MBX Biosciences had 20 more articles in the media than Kymera Therapeutics. MarketBeat recorded 33 mentions for MBX Biosciences and 13 mentions for Kymera Therapeutics. MBX Biosciences' average media sentiment score of 0.78 beat Kymera Therapeutics' score of 0.52 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	6 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MBX Biosciences beats Kymera Therapeutics on 8 of the 13 factors compared between the two stocks.

How does MBX Biosciences compare to Qiagen?

MBX Biosciences (NASDAQ:MBX) and Qiagen (NYSE:QGEN) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

MBX Biosciences has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Qiagen has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

Qiagen has a net margin of 19.16% compared to MBX Biosciences' net margin of 0.00%. Qiagen's return on equity of 14.40% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-24.52%	-23.59%
Qiagen	19.16%	14.40%	8.40%

Qiagen has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
Qiagen	$2.09B	3.23	$424.88M	$1.91	17.14

In the previous week, MBX Biosciences had 19 more articles in the media than Qiagen. MarketBeat recorded 33 mentions for MBX Biosciences and 14 mentions for Qiagen. MBX Biosciences' average media sentiment score of 0.78 beat Qiagen's score of 0.20 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	6 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

70.0% of Qiagen shares are held by institutional investors. 52.2% of MBX Biosciences shares are held by company insiders. Comparatively, 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

MBX Biosciences presently has a consensus target price of $60.22, suggesting a potential upside of 60.59%. Qiagen has a consensus target price of $46.38, suggesting a potential upside of 41.68%. Given MBX Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe MBX Biosciences is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Qiagen	0 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Qiagen beats MBX Biosciences on 8 of the 15 factors compared between the two stocks.

How does MBX Biosciences compare to TG Therapeutics?

MBX Biosciences (NASDAQ:MBX) and TG Therapeutics (NASDAQ:TGTX) are both pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

MBX Biosciences has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market.

TG Therapeutics has a net margin of 65.95% compared to MBX Biosciences' net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-24.52%	-23.59%
TG Therapeutics	65.95%	88.73%	43.44%

TG Therapeutics has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
TG Therapeutics	$616.29M	10.59	$447.18M	$2.86	14.91

In the previous week, MBX Biosciences had 20 more articles in the media than TG Therapeutics. MarketBeat recorded 33 mentions for MBX Biosciences and 13 mentions for TG Therapeutics. MBX Biosciences' average media sentiment score of 0.78 beat TG Therapeutics' score of 0.41 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	6 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

58.6% of TG Therapeutics shares are owned by institutional investors. 52.2% of MBX Biosciences shares are owned by insiders. Comparatively, 10.6% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

MBX Biosciences currently has a consensus target price of $60.22, suggesting a potential upside of 60.59%. TG Therapeutics has a consensus target price of $52.50, suggesting a potential upside of 23.09%. Given MBX Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe MBX Biosciences is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
TG Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

Summary

TG Therapeutics beats MBX Biosciences on 9 of the 15 factors compared between the two stocks.

How does MBX Biosciences compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and MBX Biosciences (NASDAQ:MBX) are both pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

In the previous week, MBX Biosciences had 8 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 33 mentions for MBX Biosciences and 25 mentions for Mirum Pharmaceuticals. MBX Biosciences' average media sentiment score of 0.78 beat Mirum Pharmaceuticals' score of 0.36 indicating that MBX Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
MBX Biosciences	6 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MBX Biosciences has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
MBX Biosciences	N/A	-24.52%	-23.59%

Mirum Pharmaceuticals currently has a consensus target price of $136.42, suggesting a potential upside of 24.97%. MBX Biosciences has a consensus target price of $60.22, suggesting a potential upside of 60.59%. Given MBX Biosciences' higher possible upside, analysts clearly believe MBX Biosciences is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

Mirum Pharmaceuticals has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	12.77	-$23.36M	-$13.61	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A

Mirum Pharmaceuticals has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

Summary

Mirum Pharmaceuticals beats MBX Biosciences on 7 of the 13 factors compared between the two stocks.

Get MBX Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBX vs. The Competition

Export

Metric	MBX Biosciences	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.76B	$751.85M	$4.27B	$12.20B
Dividend Yield	N/A	4.84%	6.10%	5.30%
P/E Ratio	-16.97	1.58	23.37	25.58
Price / Sales	N/A	117.64	157.54	78.84
Price / Cash	N/A	20.07	51.43	55.34
Price / Book	4.08	7.73	37.09	6.66
Net Income	-$86.97M	-$3.64M	$114.78M	$333.63M
7 Day Performance	8.04%	3.68%	1.97%	-0.11%
1 Month Performance	14.29%	48.73%	4.00%	3.94%
1 Year Performance	N/A	102.66%	16.86%	36.07%

MBX Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBX MBX Biosciences	3.5325 of 5 stars	$37.50 +1.4%	$60.22 +60.6%	N/A	$1.76B	N/A	N/A	N/A	Trending News Analyst Forecast Analyst Revision
PCVX Vaxcyte	2.6297 of 5 stars	$53.01 +3.0%	$86.00 +62.2%	+80.5%	$7.65B	N/A	N/A	160	Options Volume
KYMR Kymera Therapeutics	2.4085 of 5 stars	$86.08 +1.7%	$118.10 +37.2%	+174.9%	$7.08B	$39.21M	N/A	170	Insider Trade
QGEN Qiagen	4.5587 of 5 stars	$33.05 -1.4%	$46.38 +40.3%	-26.1%	$6.81B	$2.09B	17.26	5,654	Earnings Report Dividend Increase Analyst Downgrade
TGTX TG Therapeutics	4.1547 of 5 stars	$42.86 -0.4%	$52.50 +22.5%	+27.8%	$6.56B	$616.29M	14.99	290

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBX) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MBX Biosciences (MBX) Competitors

MBX vs. PCVX, KYMR, QGEN, TGTX, and MIRM

How does MBX Biosciences compare to Vaxcyte?

Summary

How does MBX Biosciences compare to Kymera Therapeutics?

Summary

How does MBX Biosciences compare to Qiagen?

Summary

How does MBX Biosciences compare to TG Therapeutics?

Summary

How does MBX Biosciences compare to Mirum Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBX vs. The Competition

MBX Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MBX Biosciences (MBX) Competitors

MBX vs. PCVX, KYMR, QGEN, TGTX, and MIRM

How does MBX Biosciences compare to Vaxcyte?

Do analysts prefer MBX or PCVX?

Is MBX or PCVX more profitable?

Do institutionals and insiders have more ownership in MBX or PCVX?

Which has more risk & volatility, MBX or PCVX?

Which has preferable valuation & earnings, MBX or PCVX?

Does the media prefer MBX or PCVX?

Summary

How does MBX Biosciences compare to Kymera Therapeutics?

Do analysts prefer MBX or KYMR?

Is MBX or KYMR more profitable?

Which has more volatility and risk, MBX or KYMR?

Which has preferable valuation & earnings, MBX or KYMR?

Does the media refer more to MBX or KYMR?

Summary

How does MBX Biosciences compare to Qiagen?

Which has more risk & volatility, MBX or QGEN?

Is MBX or QGEN more profitable?

Which has preferable valuation & earnings, MBX or QGEN?

Does the media prefer MBX or QGEN?

Do institutionals and insiders have more ownership in MBX or QGEN?

Do analysts prefer MBX or QGEN?

Summary

How does MBX Biosciences compare to TG Therapeutics?

Which has more risk & volatility, MBX or TGTX?

Is MBX or TGTX more profitable?

Which has preferable earnings and valuation, MBX or TGTX?

Does the media refer more to MBX or TGTX?

Do insiders & institutionals have more ownership in MBX or TGTX?

Do analysts recommend MBX or TGTX?

Summary

How does MBX Biosciences compare to Mirum Pharmaceuticals?

Does the media favor MIRM or MBX?

Is MIRM or MBX more profitable?

Do analysts recommend MIRM or MBX?

Which has better earnings & valuation, MIRM or MBX?

Which has more volatility & risk, MIRM or MBX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBX vs. The Competition

MBX Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools